Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2023 Results Conference Call October 26, 2023 5:00 PM ET Company Participants Edward Chung - Head, IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andy Last - EVP and COO Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citi Jack Meehan - Nephron Tim Daley - Wells Fargo Conor McNamara - RBC Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

Bio-Rad Laboratories, Inc. (BIO) Q3 2023 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.33 per share, missing the Zacks Consensus Estimate of $2.87 per share. This compares to earnings of $2.60 per share a year ago.

Bio-Rad Laboratories (BIO) Q3 Earnings and Revenues Miss Estimates

Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's shares down about 11% in extended trading.

Bio-Rad Labs cuts 2023 revenue growth forecast as biotechs cut spending

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral basis, quarterly sales decreased 7.9 percent compared to the same period in 2022. COVI.

Bio-Rad Reports Third-Quarter 2023 Financial Results

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, call 888-259-6580 within the U.S., or (+1) 206-962-3782 from outside the.

Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023

Columbia Banking System

Dorian LPG

BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.

New Strong Sell Stocks for September 19th

Advance Auto Parts

Catalent

Dollar General

Estee Lauder

Enphase Energy

Etsy

KeyCorp

MarketAxess Holdings

Mosaic

Moderna

Newell Brands

Paramount Global

Insulet

ResMed

SolarEdge Technologies

Sealed Air

Walgreens

Window dressing is a deceitful practice where mutual funds and other large institutions buy high-flying stocks and sell off the losing ones just before the end of a quarter, when many funds must report their holdings.

These Stocks Could Face Selling Pressure Soon

CRISPR Therapeutics

Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over.

3 Beaten-Down Biotech Stocks Bound for a Bounce Back

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company's management will participate in a fireside chat event during Wells Fargo's 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time). A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-.

Bio-Rad to Participate in Fireside Chat During Wells Fargo's 2023 Healthcare Conference

Graphic Packaging Hld

Chicago Atlantic Real Estate Finance

BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.

New Strong Sell Stocks for August 18th

We are initiating Bio-Rad with a buy rating and FY23 warranted DCF value of $495. Share prices have fallen over 50% from the peak and are trading at a discount according to systematic DCG valuation and industry averages. BIO's investment in Sartorius accounts for approximately 62% of its total value.

Bio-Rad: A Cash Flow Returns On Investments Analysis

ARMOUR Residential REIT

BorgWarner

BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.

New Strong Sell Stocks for August 9th

Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.

Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Simon May - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Tim Daley - Wells Fargo Jack Meehan - Nephron Research Conor McNamara - RBC Capital Brandon Couillard - Jefferies Operator Good afternoon, ladies and gentlemen and welcome to the Bio-Rad Second Quarter 2023 Earnings Results Conference Call. [Operator Instructions] This call is being recorded on Thursday, August 3, 2023.

Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Call Transcript

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.55 per share. This compares to earnings of $3.38 per share a year ago.

Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a currency-neutral basis, quarterly sales decreased 0.3 percent compared to the same period in 2022. COVID-related.

Bio-Rad Reports Second-Quarter 2023 Financial Results

QIAGEN

HERCULES, Calif., & VENLO, the Netherlands--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology. The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each co.

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock. “The new share buyback authorization is consistent with our disciplined approach and demonstrates our continued commitment to using this tool as p.

Bio-Rad Announces New Share Repurchase Program

APA Corporation

Caesars Entertainment

Halliburton

Warner Bros Discovery Inc

Analysts have the typical hopes for the S&P 500 in the next 12 months. But they're especially bullish on a small handful of stocks.

10 Stocks Will Make You 30% Richer Than Others In A Year, Analysts

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, call 888-259-6580 within the U.S., access code: 94809387. From outside the.

News for Bio-Rad Laboratories Stock (BIO)